RSLS - ReShape Lifesciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1224
-0.0087 (-6.64%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.1311
Open0.1550
Bid0.0760 x 1200
Ask0.1299 x 1000
Day's Range0.1130 - 0.1690
52 Week Range0.0500 - 39.0000
Volume35,032,069
Avg. Volume2,998,017
Market Cap2.393M
Beta1.58
PE Ratio (TTM)N/A
EPS (TTM)-32.6470
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • ACCESSWIRE15 hours ago

    ReShape Lifesciences Announces Second Quarter 2018 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / August 14, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial ...

  • InvestorPlace15 hours ago

    ReShape Lifesciences: Burning Fat Wads of Shareholders’ Cash

    Unfortunately for investors, ReShape Lifesciences (NASDAQ:RSLS) seems much more effective at cash burning than fat burning. The weight loss devices company has fallen on hard times. RSLS stock has plunged more than 90% over the past month and has plummeted more than 99% over the past year.

  • ACCESSWIRE16 hours ago

    ReShape Lifesciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / ReShape Lifesciences, Inc. (NASDAQ: RSLS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern ...

  • ACCESSWIRE5 days ago

    ReShape Lifesciences Announces Termination of Underwriting Agreement for Previously-Announced Public Offering

    SAN CLEMENTE, CA / ACCESSWIRE / August 10, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the underwriting agreement for its underwritten public offering that priced on August 7, 2018 has been terminated by the company's underwriter for the offering in accordance with its terms due to Nasdaq's determination that the offering was not a public offering under the Nasdaq rules, and therefore could not be completed without shareholder approval. As a result of the termination of the underwriting agreement, no shares of common stock will be issued in the underwritten public offering. ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases.

  • ACCESSWIRE7 days ago

    ReShape Lifesciences Announces Pricing of Underwritten Public Offering of Common Stock

    SAN CLEMENTE, CA / ACCESSWIRE / August 7, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 12,514,412 shares of its common stock at a public offering price of $0.085 per share. The offering is expected to close on or about August 10, 2018, subject to the satisfaction of customary closing conditions.The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by ReShape Lifesciences, are expected to be approximately $1.06 million. All of the shares in the offering are to be sold by ReShape Lifesciences.

  • ACCESSWIRE8 days ago

    ReShape Lifesciences Announces Proposed Underwritten Public Offering of Common Stock

    SAN CLEMENTE, CA / ACCESSWIRE / August 7, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by ReShape Lifesciences.

  • ACCESSWIRE12 days ago

    ReShape Lifesciences to Host Second Quarter 2018 Conference Call on August 14, 2018

    SAN CLEMENTE, CA / ACCESSWIRE / August 3, 2018 / ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that ...

  • ACCESSWIRE13 days ago

    ReShape Lifesciences Announces Registered Direct Offering

    SAN CLEMENTE, CA / ACCESSWIRE / August 2, 2018 / ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,000,000 shares of its common stock, at a purchase price per share of $0.60, for gross proceeds of approximately $0.6 million, in a registered direct offering. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up to 1,000,000 shares of common stock. The warrants have an exercise price of $1.10 per share of common stock, will be exercisable six months from the issuance date and will expire five and one-half years from the issuance date.

  • ReShape Lifesciences Announces European Trial to Support CE-Mark of ReShape Vest
    PR Newswire15 days ago

    ReShape Lifesciences Announces European Trial to Support CE-Mark of ReShape Vest

    SAN CLEMENTE, Calif., July 31, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the Company has commenced site initiation training for the first clinical trial site that will participate in the multi-center trial of the ReShape VestTM to support CE Mark approval. Primary endpoints in this trial include percent Total Body Weight Loss and adverse event rates at 12 months. "We have been very encouraged by the results to date with our ReShape Vest, our novel, less invasive treatment option for patients battling obesity," stated Dan Gladney, Chief Executive Officer and Chairman of the Board of ReShape Lifesciences.

  • ReShape Lifesciences Announces $2.7 Million Registered Direct Offering Priced At-the-Market
    PR Newswirelast month

    ReShape Lifesciences Announces $2.7 Million Registered Direct Offering Priced At-the-Market

    SAN CLEMENTE, Calif., July 11, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,241,382 shares of its common stock, at a purchase price per share of $2.05, for gross proceeds of approximately $2.55 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up to 1,241,382 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $0.15 million. The warrants have an exercise price of $2.06 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • ReShape Lifesciences Expands Intra-gastric Balloon Business to Include Brigham and Women's Hospital in Boston
    PR Newswirelast month

    ReShape Lifesciences Expands Intra-gastric Balloon Business to Include Brigham and Women's Hospital in Boston

    SAN CLEMENTE, Calif., July 10, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the successful implant of the first ReShape Balloon™ at the Brigham and Women's Hospital in Boston, MA. The implant was performed by Scott Shikora, MD, Director of the Center for Metabolic and Bariatric Surgery at Brigham and Women's Hospital.  Dr. Shikora, who serves as Chief Medical Officer at ReShape Lifesciences, is also a past president of the American Society for Metabolic and Bariatric Surgery (ASMBS).

  • ReShape Lifesciences Announces Acceptance of Abstract to be Presented at IFSO Annual Conference
    PR Newswire2 months ago

    ReShape Lifesciences Announces Acceptance of Abstract to be Presented at IFSO Annual Conference

    SAN CLEMENTE, Calif., June 27, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the company has had an abstract accepted by the scientific committee of the 23rd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). About ReShape Lifesciences Inc. ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases.

  • ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market
    PR Newswire2 months ago

    ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market

    SAN CLEMENTE, Calif., June 20, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 469,490 shares of its common stock, at a purchase price per share of $3.07, for gross proceeds of approximately $1.44 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up to 469,490 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $0.06 million. The warrants have an exercise price of $3.08 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest
    PR Newswire2 months ago

    ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest

    SAN CLEMENTE, Calif., June 19, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Number 10010441 entitled "Gastric Restriction Device for Treating Obesity," which covers a patent application regarding the Company's Gastric Vest System (the "ReShape VestTM"). "The ReShape Vest is a novel and ground-breaking advancement in the obesity space.  This patent allowance represents a key milestone towards our launch of this revolutionary product for patients suffering from obesity and our physician customers who treat these patients" said Dan Gladney, Chairman and Chief Executive Officer of ReShape Lifesciences™.

  • Is ReShape Lifesciences Inc (NASDAQ:RSLS) Undervalued?
    Simply Wall St.2 months ago

    Is ReShape Lifesciences Inc (NASDAQ:RSLS) Undervalued?

    ReShape Lifesciences Inc (NASDAQ:RSLS), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM over the last few months,Read More...

  • ReShape Lifesciences (RSLS) Enters Oversold Territory
    Zacks2 months ago

    ReShape Lifesciences (RSLS) Enters Oversold Territory

    ReShape Lifesciences Inc. (RSLS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

  • ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market
    PR Newswire2 months ago

    ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market

    SAN CLEMENTE, Calif., June 7, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 374,572 shares of its common stock, at a purchase price per share of $3.92, for gross proceeds of approximately $1.47 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up to 280,929 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $0.03 million. The warrants have an exercise price of $3.93 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • ReShape Lifesciences Assembles World Class Scientific Advisory Board
    PR Newswire2 months ago

    ReShape Lifesciences Assembles World Class Scientific Advisory Board

    SAN CLEMENTE, Calif. , June 6, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the ...

  • ReShape Lifesciences Announces New Patent Grant Expanding its Bioelectronic and Neuromodulation Portfolio
    PR Newswire2 months ago

    ReShape Lifesciences Announces New Patent Grant Expanding its Bioelectronic and Neuromodulation Portfolio

    ReShape Lifesciences recently presented results that utilized this intellectual property in a diabetic rat study that looked at the effect of multi-site electrical neuromodulation via the vagus nerve.  The study involved the simultaneous nerve pacing and neuro-blocking of two branches of the vagus nerve, innervating the pancreas and the liver, respectively, followed by continuous measurement of plasma glucose. Results showed that glycemic control was significantly increased following an elevated glucose challenge in the ReShape Lifesciences neuromodulation rats compared to those in the control group.

  • ReShape Lifesciences Provides Update on FDA Letter to Health Care Providers Related to Intragastric Balloons
    PR Newswire2 months ago

    ReShape Lifesciences Provides Update on FDA Letter to Health Care Providers Related to Intragastric Balloons

    Conference Call Scheduled for June 4, 2018 at 1:30 PM Pacific Time SAN CLEMENTE, Calif. , June 4, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical ...

  • ReShape Lifesciences Announces 1-for-15 Reverse Stock Split
    PR Newswire2 months ago

    ReShape Lifesciences Announces 1-for-15 Reverse Stock Split

    SAN CLEMENTE, Calif., June 1, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-15 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on June 4, 2018. At that time, each 15 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price, of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms.

  • ReShape Lifesciences Inc (NASDAQ:RSLS): Does The -44.76% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.3 months ago

    ReShape Lifesciences Inc (NASDAQ:RSLS): Does The -44.76% Earnings Drop Reflect A Longer Term Trend?

    Investors with a long-term horizong may find it valuable to assess ReShape Lifesciences Inc’s (NASDAQ:RSLS) earnings trend over time and against its industry benchmark as opposed to simply looking atRead More...

  • ReShape Lifesciences to Participate at Digestive Disease Week 2018
    PR Newswire3 months ago

    ReShape Lifesciences to Participate at Digestive Disease Week 2018

    On Sunday, June 3, 2018, ReShape Lifesciences™ will be participating in two Hands-On Workshops for physicians from 9:00 AM - 11:30 AM and 1:00 PM - 3:30 PM.  These workshops will provide an opportunity for an estimated 80 physician-participants to interact with ReShape Balloon™ experts as they demonstrate the FDA-approved dual intragastric balloon device for weight loss. ReShape Lifesciences will also be participating in the ABE Annual Meeting and Reception on Friday, June 1, 2018.

  • ReShape Lifesciences Trains Eleven Surgeons in Saudi Arabia
    PR Newswire3 months ago

    ReShape Lifesciences Trains Eleven Surgeons in Saudi Arabia

    The physicians, who specialize in gastroenterology and bariatric surgery and practice in leading medical centers in Saudi Arabia, were trained by a combination of ReShape in-house customer education professionals and five seasoned representatives from the company's Saudi Arabian distribution partner. Saudi Arabia has one of the highest obesity and overweight prevalence rates in the world.

  • ReShape Lifesciences Announces Record Revenue for First Quarter 2018
    PR Newswire3 months ago

    ReShape Lifesciences Announces Record Revenue for First Quarter 2018

    SAN CLEMENTE, Calif. , May 14, 2018 /PRNewswire/ --   ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported ...